Latest News and Press Releases
Want to stay updated on the latest news?
-
CHARLOTTESVILLE, Va., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical...
-
CHARLOTTESVILLE, Va., Dec. 13, 2018 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical...
-
Poster Presentation to Focus on Phase 3 GBM Brain Cancer Clinical Trial; 40 Percent Survival Rate for Biopsy-only Patients in Phase 2 Represents Fourfold Increase Above Historical Average For Those...
-
Highlights Include FDA Approval of Phase 2 On-Ambulance Clinical Trial for Treatment of Stroke and Appointment of New Chief Financial Officer CHARLOTTESVILLE, Va., Nov. 14, 2018 (GLOBE NEWSWIRE) --...
-
Over 1,000 Attendees Expected; Opportunity to Learn About Company’s FDA Approval for Phase 2 On-Ambulance Stroke Trial and Phase 3 GMB Brain Cancer Trial Enrollment CHARLOTTESVILLE, Va., Oct. 15,...
-
CHARLOTTESVILLE, Va., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical...
-
CHARLOTTESVILLE, Va., Sept. 12, 2018 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical...
-
CHARLOTTESVILLE, Va., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), a clinical-stage biotechnology company focused on improving...
-
Diffusion Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business Update
Enrollment continues in Phase 3 GBM brain cancer trialKey European patent validated covering oral formulation of TSCPreparing for Phase 2 stroke trial with in-ambulance administration of TSC ...
-
CHARLOTTESVILLE, Va., June 12, 2018 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) (“Diffusion” or “the Company”), a clinical-stage biotechnology company focused on extending the...